The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Candel Therapeutics Inc shares valued at $7,500,000 were purchased by Manning Paul B on Dec 16 ’24. At $6.00 per share, Manning Paul B acquired 1,250,000 shares. The insider’s holdings grew to 1,303,752 shares worth approximately $11.32 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Tyagarajan Seshu sold 20,392 shares, netting a total of over 92,898 in proceeds. Following the sale of shares at $4.56 each, the insider now holds 125,657 shares.
Before that, Tak Paul Peter had sold 48,847 shares from its account. In a trade valued at $222,527, the Chief Executive Officer traded Candel Therapeutics Inc shares for $4.56 each. Upon closing the transaction, the insider’s holdings decreased to 48,847 shares, worth approximately $2.56 million.
As published in their initiating research note from H.C. Wainwright on December 02, 2022, Candel Therapeutics Inc [CADL] has been a Buy and the price target has been revised to $11. Analysts at BMO Capital Markets started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid November. As of August 23, 2021, UBS has initiated its “Buy” rating for CADL. Earlier on August 23, 2021, Jefferies initiated its rating. Their recommendation was “a Buy” for CADL stock.
Analyzing CADL Stock Performance
During the last five days, there has been a surge of approximately 0.58%. Over the course of the year, Candel Therapeutics Inc shares have jumped approximately 490.48%. Shares of the company reached a 52-week high of $14.60 on 12/11/24 and a 52-week low of $1.16 on 01/29/24. A 50-day SMA is recorded $5.80, while a 200-day SMA reached $6.31. Nevertheless, trading volume fell to 1.24 million shares from 2.24 million shares the previous day.
Support And Resistance Levels for Candel Therapeutics Inc (CADL)
According to the 24-hour chart, there is a support level at 8.03, which, if violated, would cause prices to drop to 7.37. In the upper region, resistance lies at 9.02. The next price resistance is at 9.35. RSI (Relative Strength Index) is 58.50 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.33, which suggests the price will decrease in the coming days. Percent R is at 68.05%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
